免费网站大全app,做网站一般分几种,北京高端网站建设图片大全,电脑培训班附近有吗写在前面
大概想了解下肺癌相关的知识#xff0c;开此贴做记录#xff0c;看看后续有没有相关的生信文章思路。
综述
文章名期刊影响因子Lung cancer immunotherapy: progress, pitfalls, and promisesMol Cancer37.3
常见治疗手段有surgery, radiation therapy, chemoth…写在前面
大概想了解下肺癌相关的知识开此贴做记录看看后续有没有相关的生信文章思路。
综述
文章名期刊影响因子Lung cancer immunotherapy: progress, pitfalls, and promisesMol Cancer37.3
常见治疗手段有surgery, radiation therapy, chemotherapy, and targeted drug therapy 。Medical management易由于治疗抵抗性增加而复发。免疫治疗可生成 immunological memory generation免疫学记忆从而克服该缺点。adoptive cell therapy (CAR T, TCR, TIL)将会在本文中被讨论。没有原癌基因驱动的病人通过阻断PD1/PDL1检查点也能取得良好疗效。疫苗联合ICI免疫检查抑制剂能实现很好治疗效果。 文章目的the present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, the review also explores the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens. Finally, ongoing clinical trials, significant obstacles, and the future outlook of this treatment strategy are also highlighted to boost further research in the field. 摘要 肺癌根据who的标准可分为非小细胞肺癌约占85%还可细分为肺腺癌、肺鳞癌、大细胞癌与小细胞肺癌15%。转移后的肺癌五年生存率低。低剂量CT是诊断金标准但也存在效率低、假阳性高等问题。传统治疗方式化疗与放疗有诸多问题目前提倡的是针对突变的靶向治疗联合化疗。 非小细胞分为两种亚型预后都很差a limited disease SCLC (LD-SCLC) and an extensive disease SCLC (ED-SCLC)中位生存期只有7-12个月。 肿瘤免疫治疗的目标The goal of cancer immunotherapy is to elicit (or re-elicit) a cellular immune response, especially the T-cell-mediated tumor-specific antigen (TSA) and tumor-associated antigens (TAA)-directed cytotoxicity that can selectively destroy a tumor 。 免疫调节药物的优点 The immune-modulatory drugs can also counter cancer cells by increasing the concentration of tumor-specific antibodies, natural killer (NK) cells, dendritic cells (DCs), macrophages (MΦ), and cytokines in the blood plasma。 肺癌对免疫治疗表现不感冒的原因 lung cancer reduce the overall immunological response by modulating the T-cell mediated cytotoxicity, secretion of immune-suppressive cytokines, and loss of major histocompatibility complex (MHC) expression。 免疫治疗的方式Immunotherapy treatment types include therapeutic vaccines, immune modulators, autologous cellular therapies, and monoclonal antibodies (mAbs) directed against checkpoint inhibitor signals associated with activated T-cells and/or with cancer cells。
癌型主要特点生存期月LUAD1.独立年龄、性别、吸烟史 2.发展慢,易发现45LUSC1.与吸烟史强相关 2.跟吸烟相关的体细胞基因、通路改变44LCC1.与吸烟史相关 2.非前两种即为该类型34若为腺鳞癌仅有26个月若为非常见的LUAD有95个月
相关的基因突变: KRAS、ALK、C-MET、RET、BRAF V1E、ROS53、NTRK、TP2 和 ERBB2 HER40,肿瘤细胞上特异抗原或新抗原上的基因突变来躲避t细胞适应性免疫反应。
三信号通路激活经典t细胞 信号1APC通过与naive t cell 同源的 TCR 将MHC I 分子上的抗原肽传递给naive t cell。 新号2interaction of DC-specific CD80/86 and T cells-specific CD28 receptor 对t细胞的激活很重要 信号3DCs further secrete pro-inflammatory cytokines (signal 3) to induce T cells toward antigen-specific antitumor response
学习相关的免疫知识
来源https://www.bilibili.com/video/BV1m54y1v7HM/?spm_id_from333.337.search-card.all.clickvd_source74afe31b29c85e8f5a1afbc0d0ec17f0
细胞主要特点生存期月B细胞记忆B细胞可变成浆细胞浆细胞可产生抗体NK细胞先天免疫识别异体功效较差T细胞记忆T细胞可变T毒性细胞特异免疫杀伤力强T辅助细胞生成细胞因子活化B细胞
细胞主要特点生存期月中性粒细胞嗜酸性粒细胞杀伤寄生虫单核细胞树突细胞弥合先天与适应免疫巨噬细胞清理残渣肥大细胞变态反应
